Merck strikes deal with antibody discovery startup
BioPharma Dive
In an R D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets.
pharminent
March 31, 2026 (Last updated: March 31, 2026)
BioPharma Dive
In an R D collaboration worth as much as $838 million, Merck will lean on Infinimmune to discover immune cell-directed antibodies for multiple targets.
